NASDAQ:PETS PetMed Express 4/15/2024 Earnings Report $3.05 +0.01 (+0.33%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$3.05 0.00 (0.00%) As of 09/5/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast PetMed Express EPS ResultsActual EPS-$0.10Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/APetMed Express Revenue ResultsActual Revenue$65.32 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/APetMed Express Announcement DetailsQuarterDate4/15/2024TimeN/AConference Call DateN/AConference Call TimeN/AUpcoming EarningsPetMed Express' Q4 2025 earnings is scheduled for Tuesday, September 9, 2025, with a conference call scheduled at 6:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesEarnings HistoryCompany Profile PetMed Express Earnings HeadlinesPetMed Express (NASDAQ:PETS) Stock Rating Upgraded by Wall Street ZenSeptember 7 at 2:01 AM | americanbankingnews.comPetMed Express Faces Nasdaq Compliance DeadlineAugust 25, 2025 | tipranks.comWashington prepares for warWhile the headlines obsess over overseas conflicts, Washington has been quietly preparing for something much bigger here at home. Emergency powers are being invoked, trillions are being mobilized, and the scale rivals anything we’ve seen since WWII. According to Porter Stansberry and Jeff Brown, a new economic arms race is already underway — one that could reshape markets, redirect capital, and impact billions of lives. They’ve just released an urgent briefing that explains what’s really happening behind the scenes, and which companies are positioned to benefit most.September 7 at 2:00 AM | Porter & Company (Ad)PetMed Express, Inc. Investors: Company Investigated by the Portnoy Law FirmAugust 19, 2025 | globenewswire.comPetMeds Investor ALERT: Block & Leviton Investigating PetMed Express For Securities Fraud; ...August 18, 2025 | gurufocus.comPetMeds Investor ALERT: Block & Leviton Investigating PetMed Express For Securities Fraud; Investors Should Contact the Firm To Potentially Recover LossesAugust 18, 2025 | globenewswire.comSee More PetMed Express Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like PetMed Express? Sign up for Earnings360's daily newsletter to receive timely earnings updates on PetMed Express and other key companies, straight to your email. Email Address About PetMed ExpressPetMed Express (NASDAQ:PETS) operates as an online and catalog-based pet pharmacy and retail supplier under the 1-800-PetMeds brand name. The company distributes prescription and non‐prescription medications, nutritional supplements, flea and tick control products, and a range of pet health supplies directly to consumers. Through its licensed veterinary pharmacy in Delray Beach, Florida, PetMed Express fills orders for dogs, cats and other companion animals, offering both branded and generic products alongside its own private‐label formulations. Founded in 1996 by Marc Puleo, PetMed Express built its business on the premise of convenience and cost savings for pet owners seeking reliable access to veterinary medications. The company launched its initial public offering in 2000 and has since developed an in‐house team of veterinarians and pharmacy professionals to review prescriptions and provide customer support. With a multi‐channel approach that includes online ordering, telephone service and direct mail catalogs, PetMed Express seeks to simplify the process of obtaining essential pet health products. PetMed Express primarily serves customers across the United States, with select offerings available in Canada. Its operations center around a fulfillment facility in Florida, supported by a network of third‐party carriers for nationwide delivery. The company is led by its founder and Chief Executive Officer, Marc Puleo, who oversees strategy and business development alongside a management team experienced in pharmaceutical distribution and e-commerce. PetMed Express continues to focus on expanding its product portfolio, enhancing digital capabilities and maintaining compliance with regulatory standards in veterinary pharmacy.Written by Jeffrey Neal JohnsonView PetMed Express ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Why DocuSign Could Be a SaaS Value Play After Q2 EarningsAffirm Crushes Earnings Expectations, Turns Bears into BelieversAmbarella's Earnings Prove Its Edge AI Strategy Is a WinnerWhat to Watch for From D-Wave Now That Earnings Are DoneDICKS’s Sporting Goods Stock Dropped After Earnings—Is It a Buy?NVIDIA's Earnings Show a Green Light for Taiwan Semiconductor After Earnings Miss, Walmart Is Still a Top Consumer Staples Play Upcoming Earnings Synopsys (9/9/2025)Oracle (9/9/2025)Adobe (9/11/2025)FedEx (9/18/2025)Micron Technology (9/23/2025)AutoZone (9/23/2025)Cintas (9/24/2025)Costco Wholesale (9/25/2025)Accenture (9/25/2025)NIKE (9/30/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
